More on Merck (MRK) Q3 earnings: FY2012 guidance narrowed to EPS of $3.78-$3.82 from $3.75-$3.85. Forgetting currency issues, revenue is expected at or near 2011 level. Singulair sales -55% Y/Y. Patent expires in Europe in Feb. and company expects declining sales there similar to what happened in the U.S. Januvia/Janumet sales +15%, Zetia/Vytorin sales -1%. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 6:05PM)
at MarketWatch.com (Mon, 11:08AM)
at CNBC.com (Feb 4, 2015)
at MarketWatch.com (Feb 2, 2015)
at Nasdaq.com (Jan 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs